FindTrial
Sign In

The effect of liraglutide on MMC activity, gastrointestinal hormones, hunger ratings and ad libitum food intake in healthy volunteers.

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-518641-21-00
Enrollment
15
Registered
2024-12-18
Start date
2020-02-07
Completion date
Unknown
Last updated
2024-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Brief summary

To detect changes in MMC activity after the administration of liraglutide compared to placebo.

Detailed description

A difference in gastrointestinal hormone release compared between placebo and liraglutide treatment, A difference in hunger sensations compared between placebo and liraglutide treatment, A difference in ad libitum food intake compared between placebo and liraglutide treatment, A difference in whole blood glucose levels compared between placebo and liraglutide treatment

Interventions

DRUGSALINE
DRUGVictoza 6 mg/ml solution for injection in pre-filled pen

Sponsors

UZ Leuven
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Design outcomes

Primary

MeasureTime frame
To detect changes in MMC activity after the administration of liraglutide compared to placebo.—

Secondary

MeasureTime frame
A difference in gastrointestinal hormone release compared between placebo and liraglutide treatment, A difference in hunger sensations compared between placebo and liraglutide treatment, A difference in ad libitum food intake compared between placebo and liraglutide treatment, A difference in whole blood glucose levels compared between placebo and liraglutide treatment—

Countries

Belgium

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026